A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes

Japanese Journal of Clinical Oncology

Volumn 40, Issue 7, 2010, Pages 613-619

  Aoyama, Kei ^a   Kamio, Takako ^a   Nishikawa, Toshio ^a   Kameoka, Shingo ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; FISH; HER2; IHC; Metastatic lymph nodes; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CLINICAL ARTICLE; COMPARATIVE STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2;

EID: 77954453765     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq019     Document Type: Article

References (35)

1. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 1998;58:448-52.
2. Ross JS, Fletcher JA. The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-28.
3. Thor A, Berry D, Budman D, Muss H, Kute T, Henderson C, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-70.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
5. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
7. Tsuda H. Molecular diagnosis of breast cancer. J Jpn Surg Soc 2002;103:487-91 (in Japanese with English abstract).
8. Nemoto Y, Ookawa T, Soeda Y, Itou I, Miyachi K, Nanba M, et al. Correlation of HER-2 protein expression and clinicopathological factor in primary breast cancer. J Jpn Coll Surg 2000;27:835-40 (in Japanese with English abstract).
9. Tokuda H, Suzuki I, Saitou Y, Ohta M, Tajima T. Clinical role of trastuzumabinbreastcancer.Jpn J Cancer Clin 2002;48:119-25 (in Japanese with English abstract).
10. Niehans GA, Singleton TP, Dykoski D, Kiang DT. Stability of HER2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85:1230-5.
11. Symmans WF, Liu J, Knowles DM, Inghirami G. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 1995;26:210-6.
12. Masood S, Bui MM. Assessment of Her2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000;30:259-65.
13. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, et al. c-erbB-2 protein overexpression and p-53immunocreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73:17-20.
14. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of Her2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-6.
15. Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, et al. Evaluation of Her2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001;12:615-20.
16. Tuziak T, Olszewski WP, Olszewski W, Pienkowski T. Expression of HER2/neu in primary and metastatic breast cancer. Pol J Pathol 2001;52:21-6.
17. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, et al. Her2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94:2169-73.
18. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of Her-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
19. Edgerton SM, Moore D, II, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11:214-21.
20. Gong Y, Booser DL, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-9.
21. Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohnen RL, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3-11.
22. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008;122:999-1004.
23. Takeo S, Kamio T, Aoyama K, Nishikawa T, Kameona S. Assessment of HER2 expression in primary lesion and their metastatic lymph nodes in breast cancer patients with positive axillary lymph nodes. JTokyo Wom Med Univ 2008;78:189-97 (in Japanese with English abstract).
24. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-7.
25. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, et al. Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598-607.
26. Dowsett M, Bartlett J, Ellis IO, Salter J, Hillis M, Mallon E, et al. Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centers. J Pathol 2003;199:418-23.
27. Kinoshita T, Kyouda S, Kashiwagi H, Torikai Y, Takeyama H, Yoshida K, et al. Assessment of HER-2/neu expression between primary breast cancers and metastatic lung and brain lesion. Jpn J Breast Cancer 2004;19:276-80 (in Japanese with English abstract).
28. Bozzeti C, Nizzoli R, Guazzi A, Flora M, Bssano C, Crafa P, et al. HER-2/neu amplification detected by fluorescence in situ hybridization on fine needle aspiretes from primary breast cancer. Ann Oncol 2002;13:1398-403.
29. Bozzetti C, Personeni N, Nizzoli R, Guazzi A, Flora M, Bassano C, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 2003;99:310-5.
30. Nizzoli R, Guazzi A, Naldi N, Franciosi V, Bozzetti C. HER-2/neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer. Acta Cytol 2005;49:27-30.
31. Tapia C, Savic S, Wanger U, Schonegg R, Novotny H, Grilli B, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:31-9.
32. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000;89:329-36.
33. Luftner D, Luke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin Biochem 2003;36:233-40.
34. Kong SY, Nam BH, Lee KS, Kwon Y, Lee SE, Seong MW, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006;52:1510-5.
35. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007;9:74.